To those potential parents, a San Francisco startup is offering a solution: a genetic test of their embryos so they can select the one with the lowest risk of disease. “We help couples have healthy babies,” the company Orchid Inc. says of its tests for schizophrenia, Alzheimer’s, cancer and seven other diseases. Like Orchid, Genomic Prediction offers to test embryos for the risk of major maladies including diabetes and heart disease. AdvertisementBut that hasn’t stopped Orchid and Genomic Prediction, which also calls itself LifeView, from moving ahead with applying polygenic risk scores to embryos. That cycle can cost $15,000 before adding the costs of the genetic tests.

Source: Los Angeles Times May 26, 2021 12:02 UTC